Drug Profile
Alpha-2c adrenergic receptor antagonist - Bayer HealthCare
Alternative Names: ADRA2C antagonist - Bayer; ARα 2c Rec AntLatest Information Update: 24 May 2022
Price :
$50
*
At a glance
- Originator Bayer HealthCare
- Class Foot disorder therapies
- Mechanism of Action Alpha 2c adrenergic receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Unspecified
- Discontinued Diabetic foot ulcer
Most Recent Events
- 19 May 2022 Discontinued - Phase-I for Diabetic foot ulcer in Germany (unspecified route) (Bayer pipeline, May 2022)
- 19 May 2022 Phase-I clinical trials in Unspecified in Germany (unspecified route) before May 2022 (Bayer pipeline, May 2022)
- 26 Aug 2021 Phase I development for Diabetic foot ulcer is ongoing Germany (Bayer pipeline, August 2021)